Emmanuelle Gras, Trang T T Vu, Nhu T Q Nguyen, Vuvi G Tran, Yanjie Mao, Nguyen D Tran, Nam H Mai, Oliver X Dong, David H Jung, Natalia L P P Iorio, Helvecio C C Povoa, Marcos Gabriel Pinheiro, Fabio Aguiar-Alves, William J Weiss, Bo Zheng, Lily I Cheng, Charles K Stover, Bret R Sellman, Antonio DiGiandomenico, Laure Gibault, Florent Valour, Binh An Diep
BACKGROUND: New drugs targeting antimicrobial resistant pathogens, including Pseudomonas aeruginosa , have been challenging to evaluate in clinical trials, particularly for the non-ventilated hospital-acquired pneumonia and ventilator-associated pneumonia indications. Development of new antibacterial drugs is facilitated by preclinical animal models that could predict clinical efficacy in patients with these infections. METHODS: We report here an FDA-funded study to develop a rabbit model of non-ventilated pneumonia with Pseudomonas aeruginosa by determining the extent to which the natural history of animal disease reproduced human pathophysiology and conducting validation studies to evaluate whether humanized dosing regimens of two antibiotics, meropenem and tobramycin, can halt or reverse disease progression...
2023: Frontiers in Cellular and Infection Microbiology